M. Zimmermann

Ursula Creutzig, Martin Zimmermann, Frank Griesinger, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009

M. Schrappe, S. Izraeli, A. Attarbaschi, 2022, Leukemia.

ANDREIA FILIPA MADUREIRA GUIMARÃES VANIN-2, A POTENTIAL PROGNOSTIC MARKER OF RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA

Martina, Paulina, Bourquin, 2015 .

Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.

M. Schrappe, G. Henze, L. Löning, 2000, Blood.

Clinical characteristics and treatment outcome of infants with non‐Hodgkin lymphoma

W. Klapper, B. Burkhardt, M. Schrappe, 2007, British journal of haematology.

Non‐anaplastic peripheral T‐cell lymphoma in children and adolescents – a retrospective analysis of the NHL‐BFM study group

W. Klapper, B. Burkhardt, A. Attarbaschi, 2015, British journal of haematology.

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma

W. Klapper, B. Burkhardt, M. Schrappe, 2017, Haematologica.

Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk.

W. Blum, H. Wex, M. Zimmermann, 2005, The Journal of clinical endocrinology and metabolism.

[Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].

D. Reinhardt, U. Creutzig, M. Zimmermann, 2003, Klinische Padiatrie.

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

J. Harbott, M. Schrappe, G. Henze, 2010, Leukemia.

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

J. Harbott, M. Schrappe, G. Henze, 2000, Leukemia.

Definition of a standard‐risk group in children with AML

G. Henze, G. Henze, N. Graf, 1999, British journal of haematology.

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

S. Meshinchi, M. Heinrich, A. Harlow, 2005, Leukemia.

CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype.

B. Burkhardt, M. Schrappe, R. Parwaresch, 2005 .

Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.

O. Hrusak, M. Schrappe, S. Izraeli, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

D. Reinhardt, J. Starý, U. Creutzig, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Christian Urban, Martin Zimmermann, Martin Stanulla, 2007, Blood.

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

B. Burkhardt, M. Schrappe, R. Parwaresch, 2004, Blood.

Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

W. Hiddemann, M. Schrappe, G. Henze, 1994, Blood.

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.

M. Zucchetti, J. Gerss, M. Schrappe, 2020, Haematologica.

Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray

Martin Zimmermann, Carl W. Miller, Rolf Koehler, 2008, Proceedings of the National Academy of Sciences.

[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group].

M. Schrappe, G. Fleischhack, N. Graf, 1994, Klinische Padiatrie.

[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].

M. Schrappe, W. Ebell, A. Claviez, 1994, Klinische Padiatrie.

Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy.

W. Klapper, B. Burkhardt, A. Attarbaschi, 2020, Blood.

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.

W. Klapper, F. Berthold, B. Burkhardt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.

M. Muckenthaler, P. Lichter, S. Pfister, 2009, Blood.

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function

M. Muckenthaler, M. Schrappe, W. Ludwig, 2010, Leukemia.

Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia

R. Pieters, J. Cayuela, A. Baruchel, 2011, Haematologica.

Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia.

B. Meissner, I. Heřmanová, A. Teigler‐Schlegel, 2014, Human molecular genetics.

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents

F. Berthold, M. Schrappe, G. Henze, 2018, Haematologica.

Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.

W. Klapper, B. Burkhardt, P. Hoffmann, 2020, Blood.

Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia

M. Schrappe, A. Attarbaschi, A. Möricke, 2013, Klinische Pädiatrie.

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia

B. Meissner, M. Schrappe, A. Attarbaschi, 2012, Haematologica.

Outcomes after induction failure in childhood acute lymphoblastic leukemia.

C. Pui, A. Baruchel, L. Silverman, 2012, The New England journal of medicine.

Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial

M. Schrappe, M. Valsecchi, J. Starý, 2007, The Lancet.

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

W. Hiddemann, J. Harbott, M. Schrappe, 2000, Blood.

Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

F Lampert, J. Harbott, M. Schrappe, 1998, Blood.

Chromosome-Positive ( Ph 1 ) Childhood Acute Lymphoblastic Leukemia : Good Initial Steroid Response Allows Early Prediction of a Favorable Treatment Outcome

J. Harbott, M. Schrappe, C. Bartram, 1998 .

Comparative genomic hybridization in childhood acute lymphoblastic leukemia: correlation with interphase cytogenetics and loss of heterozygosity analysis.

A. Jauch, B. Schoell, A. Teigler‐Schlegel, 2001, Cancer genetics and cytogenetics.

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

J. Harbott, M. Schrappe, G. Henze, 2000, Leukemia.

Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.

R. Pieters, A. Veerman, J. Harbott, 2002, Blood.

Anemia and survival in childhood acute lymphoblastic leukemia

M. Schrappe, B. Schafer, W. Ludwig, 2008, Haematologica.

TREATMENT OF CHILDHOOD ALL 3123 an increased leukemic cell

W. Hiddemann, M. Schrappe, G. Henze, 2002 .

Daunorubicin during delayed intensification decreases the incidence of infectious complications – a randomized comparison in trial CoALL 08-09

A. Borkhardt, G. Escherich, M. Horstmann, 2018, Leukemia & lymphoma.

MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB

M. Muckenthaler, M. Schrappe, D. Grimm, 2018, BMC Cancer.

childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Late MRD response determines relapse risk overall and in subsets of

B. Schäfer, M. Schrappe, C. Bartram, 2013 .

Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome

B. Meissner, A. Teigler‐Schlegel, M. Schrappe, 2012, Haematologica.

Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen‐breakage syndrome): a retrospective survey

B. Burkhardt, A. Borkhardt, M. Schrappe, 2011, British journal of haematology.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

J. V. van Dongen, B. Schäfer, M. Schrappe, 2011, Blood.

Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.

S. Ogawa, J. Harbott, M. Schrappe, 2009, International journal of oncology.

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.

Carl W. Miller, S. Ogawa, K. Hemminki, 2007, Blood.

High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.

H. Schünemann, M. Schrappe, S. Izraeli, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

M. Schrappe, K. Welte, W. Ludwig, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL‐BFM 95

M. Schrappe, R. Beier, A. Reiter, 2005, Pediatric blood & cancer.

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture.

M. Schrappe, G. Mann, L. Löning, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic C erebrospinal F luid E xamination i n C hildren W ith Acute L ymphoblastic L eukemia: S ignificance o f L ow L eukocyte Counts W ith B lasts o r T raumatic L umbar P uncture

M. Schrappe, G. Mann, A. Reiter, 2003 .

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

M. Schrappe, G. Basso, W. Ludwig, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.

A. Borkhardt, J. Harbott, M. Schrappe, 1996, Leukemia.

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.

J. Harbott, W. Ludwig, C. Sperling, 1995, Blood.

Homozygous Deletion of the p16 Gene in Childhood Acute Lymphoblastic Leukemia

Carl W. Miller, C. Bartram, A. Tobler, 1997 .

NUP98/JARID1A Is a New Recurrent Genetic Abnormality in Pediatric Acute Megakaryoblastic Leukemia with a Distinct HOX -Gene Expression Pattern

R. Pieters, A. Baruchel, S. Meshinchi, 2012 .

NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

R. Pieters, A. Baruchel, J. V. van Galen, 2011, Blood.

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

R. Pieters, J. Harbott, D. Reinhardt, 2009, Leukemia.

MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.

C. Plass, S. Bortoluzzi, M. D. Den Boer, 2021, Blood.

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols

W. Klapper, R. Siebert, B. Burkhardt, 2017, Haematologica.

Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL‐BFM protocols

R. Eils, W. Klapper, R. Siebert, 2014, Genes, chromosomes & cancer.

The role of complete surgical resection in stage IV neuroblastoma

U. Bode, G. Fleischhack, P. Bastian, 2004, World Journal of Urology.

Non‐hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria

C. Niemeyer, H. Hasle, M. Zimmermann, 2007, Pediatric blood & cancer.

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

J. Harbott, S. Fenu, G. Basso, 1999, Leukemia.

Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.

W. Klapper, B. Burkhardt, K. Pulford, 2010, Blood.

MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML

M. Fornerod, R. Pieters, A. Baruchel, 2018, Oncogene.

Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.

O. Haas, D. Reinhardt, Z. Zemanová, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia

Rob Pieters, Martin Zimmermann, Askar Obulkasim, 2015, Haematologica.

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

D Rizopoulos, D. Rizopoulos, M. D. Den Boer, 2016, Leukemia.

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.

S. Raimondi, N. Heerema, J. Harbott, 2007, Blood.

Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

S. Raimondi, D. Liang, D. Reinhardt, 2015, Blood.

Clinical Outcome of Patients with Childhood Acute Lymphoblastic Leukaemia and an Initial Leukaemic Blood Blast Count of Less than 1000 per Microliter

M. Schrappe, K. Welte, M. Stanulla, 2001, Klinische Padiatrie.

[Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].

T. Klingebiel, J. Ritter, U. Creutzig, 1996, Klinische Pädiatrie.

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia

B. Meissner, C. Franceschi, A. Teigler‐Schlegel, 2011, Leukemia.

Expression of CD56 defines a distinct subgroup in childhood T‐ALL with inferior outcome. Results of the ALL‐BFM 2000 trial

M. Schrappe, W. Ludwig, L. Karawajew, 2018, British journal of haematology.

Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia

E. Kremmer, C. Stocking, M. Horstmann, 2013, The Journal of experimental medicine.

Aberrant ZNF 423 impedes B cell differentiation and is linked to adverse outcome of ETV 6-RUNX 1 negative B precursor acute lymphoblastic leukemia

E. Kremmer, C. Stocking, M. Horstmann, 2013 .

Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases

A. Borkhardt, A. Teigler‐Schlegel, J. Harbott, 2002, Leukemia.

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

M. Tiemann, M. Schrappe, A. Chott, 1999, Blood.

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report

D. Reinhardt, J. Starý, D. Steinbach, 2012, Leukemia.

Loss of heterozygosity on chromosome 6q14–q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma

K. Strauch, B. Burkhardt, J. Harbott, 2006, Leukemia.

Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups

C. Klein, M. Schrappe, K. Welte, 2005, Leukemia.

Trial NHL-BFM 90 Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored

M. Tiemann, M. Schrappe, A. Chott, 2013 .

Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial

U. Bode, R. Kortmann, S. Rutkowski, 2014, Journal of Neuro-Oncology.

Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

J. Harbott, O. Haas, G. Basso, 1997, Blood.

The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.

M. Yaspo, E. Mejstrikova, M. Schrappe, 2020, Blood advances.

High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

Martin Zimmermann, Martina U. Muckenthaler, Martin Stanulla, 2014, Haematologica.

ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations

M. König, J. Harbott, O. Haas, 2008, Clinical Cancer Research.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

B. Meissner, J. Stuchly, A. Teigler‐Schlegel, 2015, Leukemia.

Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence

W. Klapper, R. Siebert, B. Burkhardt, 2019, Leukemia.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

B. Meissner, J. Stuchly, A. Teigler‐Schlegel, 2014, Leukemia.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

B. Schäfer, M. Schrappe, C. Bartram, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.

S. Raimondi, R. Ries, S. Meshinchi, 2018, Blood.

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

D. Steinemann, T. Révész, O. Haas, 2019, Haematologica.

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia

B. Wood, M. Schrappe, C. Bartram, 2018, JNCI cancer spectrum.

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

J. Harbott, M. Schrappe, C. Bartram, 2016, Blood.

Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies.

H. Christiansen, T. Pietsch, U. Bode, 2014, International journal of radiation oncology, biology, physics.

ETV 6-NCOA 2 : A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid andMyeloid Markers and Frequent NOTCH 1 Mutations

J. Harbott, O. Haas, S. Izraeli, 2008 .

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia

M. Schrappe, A. Alsadeq, A. Möricke, 2017, Haematologica.

Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study

S. Raimondi, G. Leverger, S. Ha, 2021, Pediatric blood & cancer.

M. Muckenthaler, J. Vijayakrishnan, R. Houlston, 2023, Journal of Experimental & Clinical Cancer Research.

Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08‐09 trial

G. Escherich, M. Horstmann, M. Zimmermann, 2013, British journal of haematology.

Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

M. Tiemann, M. Schrappe, R. Parwaresch, 2000, Blood.

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.

M. Schrappe, C. Bartram, M. Eichelbaum, 2005, JAMA.

Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML – Results from Study AML-BFM 2004

D. Reinhardt, T. Klingebiel, B. Gruhn, 2015, Klinische Pädiatrie.

myeloid leukemia: results of an international retrospective study Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute

S. Raimondi, R. Pieters, N. Heerema, 2013 .

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study

D. Reinhardt, J. Klusmann, T. Klingebiel, 2012, Haematologica.

Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

S. Raimondi, R. Pieters, N. Heerema, 2011, Blood.

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

S. Raimondi, R. Pieters, N. Heerema, 2009, Blood.

Prognostic impact of IKZF1 deletions in association with vincristine–dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95

M. Schrappe, A. Möricke, C. Kratz, 2017, Leukemia.

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

Ursula Creutzig, Norbert Graf, Martin Zimmermann, 2013, Blood.

Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups

D. Reinhardt, F. Locatelli, R. Masetti, 2017, Pediatric blood & cancer.

Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival

D. Reinhardt, T. Klingebiel, J. Starý, 2015, Leukemia.

CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML‐BFM98 and 2004

D. Reinhardt, J. Starý, G. Fleischhack, 2011, Pediatric blood & cancer.

Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.

J. Ritter, U. Creutzig, M. Zimmermann, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second malignancies after treatment of childhood non-Hodgkin lymphoma – a report of the Berlin-Frankfurt-Muenster study group

W. Klapper, B. Burkhardt, M. Schrappe, 2020, Haematologica.

Non‐leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma

S. Bens, W. Klapper, R. Siebert, 2019, Genes, chromosomes & cancer.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

V. V. D. van der Velden, D. Reinhardt, J. Klusmann, 2018, Blood advances.

Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study

R. Pieters, B. Johansson, D. Reinhardt, 2014, Haematologica.

Down syndrome Treatment and prognostic impact of transient leukemia in neonates with

D. Reinhardt, J. Klusmann, U. Creutzig, 2013 .

Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

D. Reinhardt, J. Klusmann, U. Creutzig, 2008, Blood.

Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

D. Reinhardt, D. Steinbach, B. Gruhn, 2014, Clinical Cancer Research.

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.

D. Reinhardt, J. Klusmann, C. Zwaan, 2017, Blood.

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.

A. Borkhardt, G. Escherich, M. Horstmann, 2021, Haematologica.

Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia

E. Froňková, M. Schrappe, C. Bartram, 2016, British journal of haematology.

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

J. Boos, J. Ritter, U. Creutzig, 1998, Leukemia.

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.

W. Klapper, M. Pillon, A. Reiter, 2014, Blood.

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence.

W. Klapper, B. Burkhardt, A. Attarbaschi, 2013, Blood.

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis

M. Pillon, A. Reiter, Angelo Rosolen, 2013, Leukemia.

Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study.

W. Klapper, B. Burkhardt, A. Attarbaschi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.

W. Klapper, B. Burkhardt, J. Harbott, 2007, Blood.

Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

W. Klapper, R. Siebert, B. Burkhardt, 2006, Blood.

Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.

B. Burkhardt, M. Schrappe, W. Ludwig, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescence

B. Burkhardt, M. Schrappe, R. Parwaresch, 2005, British journal of haematology.

Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.

M. Tiemann, M. Schrappe, R. Parwaresch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

M. Tiemann, M. Schrappe, R. Parwaresch, 2001, Blood.

Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies.

M. Tiemann, M. Schrappe, R. Parwaresch, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia

W. Kamps, H. Boezen, U. Creutzig, 2008, Clinical Cancer Research.

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial

D. Reinhardt, J. Klusmann, U. Creutzig, 2015, Annals of Hematology.

leukemia patients. Results and conclusions of the multicenter trial Chemotherapy in 998 unselected childhood acute lymphoblastic

W. Hiddemann, M. Schrappe, G. Henze, 2011 .

Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols

W. Klapper, B. Burkhardt, M. Schrappe, 2011, Leukemia.

Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact

K. Strauch, W. Klapper, B. Burkhardt, 2008, Leukemia & lymphoma.

Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.

W. Klapper, B. Burkhardt, M. Schrappe, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95

K. Welte, M. Stanulla, A. Reiter, 2006, Annals of Hematology.

Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.

B. Burkhardt, K. Welte, M. Stanulla, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy

M. Schrappe, R. Parwaresch, W. Ludwig, 2001, Annals of Hematology.

Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

D. Reinhardt, U. Creutzig, M. Zimmermann, 2007, Pediatric blood & cancer.

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97

G. Escherich, M. Horstmann, G. Janka-Schaub, 2010, Leukemia.

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

M. Schrappe, C. Bartram, M. Valsecchi, 2008 .

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

A. Teigler‐Schlegel, D. Reinhardt, J. Starý, 2011, Blood.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.

D. Reinhardt, J. Starý, U. Creutzig, 2007, Blood.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

E. Hellström-Lindberg, H. Kreipe, A. Giagounidis, 2010, Annals of Hematology.

Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98.

D. Reinhardt, U. Creutzig, M. Zimmermann, 2004, Annals of hematology.

Allo-SCT using BU, CY and melphalan for children with AML in second CR

A. Schulz, A. Borkhardt, D. Reinhardt, 2013, Bone Marrow Transplantation.

Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.

M. Schrappe, K. Welte, M. Stanulla, 2000, Blood.

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.

M. D. Den Boer, A. Borkhardt, G. Escherich, 2019, Blood advances.

Prognostic Impact of Age in Children and Adolescents with Acute Lymphoblastic Leukemia: Data from the Trials ALL-BFM 86, 90, and 95

J. Harbott, M. Schrappe, W. Ludwig, 2005, Klinische Padiatrie.

Update On the Risk of Leukemia in Genetic Subgroups of Congenital Neutropenia (CN): Comparison of Patients with Known Gene Mutations (ELA2, HAX1, WASP, G6PC3, p14).

C. Klein, D. Link, K. Welte, 2009 .

Intensive chemotherapy and bone marrow transplantation for children with acute myeloid leukemia

D. Reinhardt, T. Klingebiel, H. Gadner, 2001 .

Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis

D. Reinhardt, J. Starý, A. von Stackelberg, 2016, Pediatric blood & cancer.

Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL

A. Borkhardt, M. Schrappe, C. Eckert, 2019, Bone Marrow Transplantation.

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.

A. Attarbaschi, A. Uyttebroeck, L. Brugières, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia

M. Fornerod, R. Pieters, J. Cayuela, 2015 .

Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia

H. Schünemann, M. Schrappe, S. Igel, 2021, Leukemia.

Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes

Heather L. Mulder, Michael C. Rusch, Michael N. Edmonson, 2017, Nature Genetics.

Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia

W. Klapper, B. Burkhardt, M. Rohde, 2016, Leukemia.

TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia

M. Schrappe, A. Möricke, C. Kratz, 2019, Haematologica.

Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

W. Klapper, M. Zimmermann, I. Oschlies, 2013, Haematologica.

Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.

E. Thiel, J. Harbott, C. Schoch, 1999, Leukemia & lymphoma.

Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients

C. Klein, G. Escherich, M. Horstmann, 2020, Leukemia.

Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment

J. Harbott, D. Reinhardt, W. Ludwig, 2005, Leukemia.

Biological Entities in Acute Myelogenous Leukemia According to Morphological, Cytogenetic and Immunological Criteria: Data of Study AML-BFM-87

J. Harbott, W. Ludwig, F. Lampert, 1996 .

Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial

B. Meissner, C. Klein, L. Pape, 2014 .

The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia

M. Schrappe, K. Welte, A. Schrauder, 2005, Bone Marrow Transplantation.

Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma.

W. Klapper, I. Salaverria, B. Burkhardt, 2023, The Lancet. Haematology.

Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses

G. Henze, D. Reinhardt, J. Starý, 2010, British journal of haematology.

Nimotuzumab treatment of malignant gliomas

M. Westphal, U. Bode, M. Massimino, 2012, Expert opinion on biological therapy.

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

B. Burkhardt, A. Attarbaschi, A. Reiter, 2016, Annals of Hematology.

Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I‐BFM analysis of 333 children

D. Reinhardt, J. Wachowiak, F. Locatelli, 2020, British journal of haematology.

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia : results from Study

Ursula Creutzig, Norbert Graf, Martin Zimmermann, 2017 .

Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but not Long-term Survival

D. Reinhardt, U. Creutzig, G. Kaspers, 2014, Klinische Pädiatrie.

Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): Single‐agent therapeutic window study in relapsed AML

D. Reinhardt, G. Fleischhack, U. Creutzig, 2006, Pediatric blood & cancer.

Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia

O. Haas, D. Reinhardt, V. Sexl, 2019, HemaSphere.

No Improvement of Overall-Survival in Children with High-Risk Acute Myeloid Leukemia by Stem Cell Transplantation in 1st Complete Remission.

D. Reinhardt, T. Klingebiel, C. Peters, 2006 .

GENOMIC AND DRUG RESPONSE PROFILING OF FATAL TCF3-HLF-POSITIVE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIES RECURRENT MUTATION PATTERNS AND NOVEL THERAPEUTIC OPTIONS

J. Korbel, H. Lehrach, P. Rosenstiel, 2015 .

Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity

D. Reinhardt, J. Starý, J. Bourquin, 2010 .

Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

A. Baruchel, S. Ha, D. Reinhardt, 2009 .

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

M. Schrappe, M. Kuhlen, M. Valsecchi, 2019, Leukemia.

CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.

C. Klein, K. Welte, T. Jack, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epstein-Barr virus infection in Western European pediatric non-Hodgkin lymphomas.

H. Stein, R. Parwaresch, M. Hummel, 2003, Blood.

Risk Factors for Survival in Children with Refractory AML Treated According to AML Relapse Strategies

J. Ritter, U. Creutzig, M. Zimmermann, 1998 .

Wilms’ Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection

R. Pieters, A. Baruchel, D. Reinhardt, 2008 .

A randomised phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia

G. Fleischhack, M. Zimmermann, B. Gibson, 2001 .

Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group

W. Klapper, R. Siebert, B. Burkhardt, 2020, British journal of haematology.

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07‐03

G. Escherich, G. Janka-Schaub, M. Zimmermann, 2013, Pediatric blood & cancer.

Cell‐of‐origin classification by gene expression and MYC‐rearrangements in diffuse large B‐cell lymphoma of children and adolescents

R. Spang, W. Klapper, R. Siebert, 2017, British journal of haematology.

Development of a Curative Treatment within the AML-BFM Studies

D. Reinhardt, J. Ritter, U. Creutzig, 2013, Klinische Pädiatrie.

Long term survival in children with acute leukaemia and complications requiring mechanical ventilation

M. Schrappe, D. Reinhardt, H. Jürgens, 2011, Archives of Disease in Childhood.

Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?

M. Pillon, M. Zimmermann, W. Woessmann, 2022, Cancers.

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma

W. Klapper, A. Attarbaschi, M. Zimmermann, 2019, Haematologica.

Course of anti‐ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma

G. Basso, M. Pillon, M. Zimmermann, 2018, British journal of haematology.

Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics

T. Illig, M. Schrappe, A. Bergmann, 2021, Cancers.

Proposal of a Genetic Classifier for Risk Group Stratification in Pediatric T-Cell Lymphoblastic Lymphoma Reveals Significant Differences to T-Cell Lymphoblastic Leukemia

W. Klapper, B. Burkhardt, M. Rohde, 2014 .

Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children

A. Rosenwald, W. Klapper, R. Siebert, 2011, Haematologica.

Seroepidemiological analysis and literature review of the prevalence of Epstein‐Barr virus and herpesvirus infections in pediatric cases with non‐Hodgkin lymphoma in Central Europe

A. Reiter, M. Zimmermann, H. Wagner, 2019, Pediatric blood & cancer.

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012

W. Klapper, B. Burkhardt, A. Attarbaschi, 2021, Haematologica.

Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia

R. Houlston, A. Franke, M. Schrappe, 2021, Journal of clinical medicine.

Minimal Residual Disease–based Treatment is Adequate for Relapse-prone Childhood Acute Lymphoblastic Leukemia with an intrachromosomal amplification of chromosome 21: The experience of the ALL-BFM 2000 trial

A. Teigler‐Schlegel, M. König, J. Harbott, 2014, Klinische Pädiatrie.

Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood

S. Bens, R. Siebert, M. Schrappe, 2017, Pediatric blood & cancer.

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first‐line intensified treatment of pediatric patients with high‐risk acute lymphoblastic leukemia in CoALL08‐09 trial

A. Borkhardt, G. Escherich, M. Horstmann, 2022, Pediatric blood & cancer.

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia

M. Muckenthaler, M. Schrappe, M. Valsecchi, 2014, Oncotarget.

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

M. Schrappe, C. Bartram, M. Valsecchi, 2016 .

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

M. Zucchetti, M. Schrappe, M. Valsecchi, 2023, HemaSphere.

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

B. Burkhardt, M. Schrappe, M. Valsecchi, 2023, HemaSphere.

Therapeutic Drug Monitoring of Asparaginase Activity—Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial

M. Zucchetti, J. Gerss, M. Schrappe, 2017, Therapeutic drug monitoring.

Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93

H. Gadner, J. Ritter, U. Creutzig, 2001 .

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data

M. Zucchetti, J. Gerss, M. Schrappe, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM ALL 2009 study.

M. Zucchetti, J. Gerss, M. Schrappe, 2020, Therapeutic drug monitoring.

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen

M. Schrappe, M. Zimmermann, G. Cario, 2019, Haematologica.

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

R. Houlston, M. Yaspo, A. Teigler‐Schlegel, 2014 .

acute myeloid leukemia: results of study AML-BFM-87 Clinical significance of surface antigen expression in children with

J. Harbott, C. Sperling, J. Ritter, 2011 .

Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma

B. Burkhardt, M. Szczepanowski, M. Rohde, 2015, Leukemia & lymphoma.

The role of initial laparotomy and second-look surgery in the treatment of abdominal B-cell non-Hodgkin's lymphoma of childhood. A report of the BFM Group.

D. V. von Schweinitz, H. Mildenberger, A. Reiter, 1994, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.

B. Schäfer, M. Schrappe, C. Bartram, 2007 .

Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study

R. Pieters, B. Johansson, D. Reinhardt, 2010 .

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

M. Zucchetti, M. Schrappe, M. Valsecchi, 2019, Blood.

Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012

D. Reinhardt, J. Klusmann, U. Creutzig, 2016 .

Chronic myelomonocytic leukemia (CMML) in childhood

O. Haas, S. Fenu, G. Basso, 1994 .

[Improved treatment results in children with AML: Results of study AML-BFM 93].

F. Berthold, G. Henze, D. Reinhardt, 2001, Klinische Padiatrie.